Ligand-based discovery of coronavirus main protease inhibitors using MACAW molecular embeddingsArticle Published on 2023-12-012022-11-15 Journal: Journal of Enzyme Inhibition and Medicinal Chemist [Category] 치료제, [키워드] antiviral properties binding affinity cells Cheminformatics Compound compounds conducted coronavirus dataset dose-dependent inhibition drug design Drug discovery evaluate half-maximal inhibitory concentration in silico inhibitor inhibitory effect ligand-based drug design M pro Machine learning. machine-learning molecular protease Protease inhibitor screened selected thought Toxicity Virtual screening virus infectivity [DOI] 10.1080/14756366.2022.2132486 PMC 바로가기
Cotton flower metabolites inhibit SARS-CoV-2 main proteaseArticle Published on 2022-10-012022-11-15 Journal: FEBS Open Bio [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] acute respiratory syndrome anti-SARS-CoV-2 Antiviral assays biochemical biochemical assay contagious coronavirus cotton cotton flower database disease drugs effective examined exhibited half-maximal inhibitory concentration IC50s identify in vitro inhibit SARS-CoV-2 inhibited inhibitor inhibitory effect M pro main protease metabolite protease Protein safety profile SARS-CoV-2 significantly Spread tissue Treatment Vaccine variants Virtual screening virtual screening. [DOI] 10.1002/2211-5463.13477 PMC 바로가기
Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2Article Published on 2022-09-142022-11-15 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome amino acid substitution amubarvimab (BRII-196) antibody antibody cocktail Clinical efficacy Combination controls coronavirus coronavirus disease COVID-19 demonstrated Emergency use authorization epitope EUA Evolution half-maximal inhibitory concentration half-maximal inhibitory concentration (IC50) in vitro introduced less Lung pathology Lungs M252Y/S254T/T256E (YTE) mAb mAbs Modification monoclonal antibody monoclonal antibody (mAb) Mutation neutralize neutralized Neutralizing Post-infection Preclinical RBD receiving Receptor binding domain receptor binding domain (RBD) reduce reduced regions regulatory authority resulting retained romlusevimab (BRII-198) SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly Spike protein Support susceptibility therapeutic option variant Variant of concern (VOC). variants variants of concern Viral load virus virus VoC weight loss [DOI] 10.3389/fimmu.2022.980435 PMC 바로가기
A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal deliveryArticle Published on 2022-08-302022-10-05 Journal: Signal Transduction and Targeted Therapy [Category] SARS, 변종, 진단, 치료제, [키워드] acute respiratory syndrome Administered antibody approved B.1.1.529 B.1.617.2 broad-spectrum antivirals characterized circulating Clinical outcome Clinical use coronavirus Delta delta variant dosage drug effective Efficacy ENhance half-maximal inhibitory concentration hamster IC50 inhibit Intravenous injection knowledge Lungs mutants nasal nebulized neutralizing antibody omicron overcome Patient prevented Prophylactic provide Replication SARS-CoV-2 SARS-CoV-2 infections SARS-CoV-2 variant therapeutic therapeutic efficacy therapy Treatment Vaccine variant virus-neutralizing VoC VOCs [DOI] 10.1038/s41392-022-01135-3 [Article Type] Article
Anti-SARS-CoV-2 activity of various PET-bottled Japanese green teas and tea compounds in vitro다양한 PET병 일본 녹차 및 차 화합물의 시험관 내 항 SARS-CoV-2 활성Article Published on 2022-07-012022-09-11 Journal: Archives of Virology [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antiviral activity antiviral therapeutics caused Compound compounds coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 treatment demonstrated Dilution dose-dependent manner Effectiveness EGCG Epicatechin epigallocatechin epigallocatechin gallate examined gallate global public health green green tea half-maximal inhibitory concentration half-maximal inhibitory concentrations in vitro inactivated Infection infectious titers inhibit SARS-CoV-2 inhibited investigated Japanese life cycle other compound other compounds outbreak polyethylene terephthalate Prophylaxis protease SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus shown Stage the SARS-CoV-2 treat Treatment Vaccine variety viral life cycle Viral RNA virucidal [DOI] 10.1007/s00705-022-05483-x PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial6~17세 어린이 대상 ChAdOx1 nCoV-19(AZD1222) 백신의 안전성 및 면역원성: 2상 단일 맹검, 무작위, 대조 시험인 COV006의 예비 보고서Clinical Trial Published on 2022-06-112022-09-11 Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] 95% CI administration Adults adverse event adverse events age All participants anti-SARS-CoV-2 IgG antibody Antibody titre antibody titres arbitrary unit assigned AstraZeneca AZD1222 baseline capsular Cellular responses ChAdOx1 ChAdOx1 nCoV-19 children chronic respiratory conditions Concentration Controlled trial COVID-19 COVID-19 vaccine COVID-19 vaccines Cutoff Department dose doses Efficacy enrolled Fever first dose first vaccination four group four groups geometric geometric mean geometric mean ratios Geometric means group half-maximal inhibitory concentration Humoral response humoral responses immune response immune responses immunogenic immunogenicity in some intramuscular dose introduced investigators ISRCTN Laboratory laboratory-confirmed Laboratory-confirmed COVID-19 Local nucleocapsid protein Pain and tenderness participant Participants peaked Phase 2 phase 3 study preliminary report Primary outcome prime and boost raised randomised Randomly receive receiving recruitment Registered remained reported resolved respiratory response Safety safety population SARS-CoV-2 second dose second vaccination secondary outcome Serious Adverse Event Serious Adverse Events seronegative seronegative participant seronegative participants seropositive serostatus single-blind stratified study drug study groups tenderness Tolerability treatment allocation Trial vaccination Vaccine Viral viral particle were recorded [DOI] 10.1016/S0140-6736(22)00770-X PMC 바로가기 [Article Type] Clinical Trial
Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation Research Published on 2022-06-082022-10-05 Journal: Nature chemical biology [Category] COVID19(2023년), SARS, 치료제, [키워드] Activation airways binding pocket canonical cleaved effort explain feature half-maximal inhibitory concentration host cell identify implicated Infection inhibit inhibitor mechanism membrane fusion nonspecific pathogenesis of SARS-CoV-2 protease Protease inhibitor Protein proteolytic activity provide S1/S2 cleavage site SARS-CoV-2 SARS-CoV-2 S protein serine 2 specificity spike Structure the SARS-CoV-2 TMPRSS2 TMPRSS2 protease viral entry X-ray [DOI] 10.1038/s41589-022-01059-7 [Article Type] Research
Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern우려되는 SARS-CoV-2 변이체에 대한 소 락토페린 제품의 시험관 내 효능 평가Article Published on 2022-04-012022-09-11 Journal: Journal of dairy science [Category] COVID19(2023년), SARS, 변종, 신약개발, [키워드] African Analysis anti-SARS-CoV-2 Anti-SARS-CoV-2 Activity B.1.1.7 B.1.1.7 variant B.1.351 bovine cell line Characteristics Clinical significance conjunction Delta dextrose digestion Efficacy Entry mechanism entry mechanisms Evaluating glycoprotein half-maximal inhibitory concentration high-content imaging human clinical trials human lung immunomodulatory in vitro ingredient inhibit inhibited inhibitory concentration lactoferrin mechanisms microbes milk option P.1 Pathogens pepsin Protein released SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 treatment SARS-CoV-2 variant SARS-CoV-2 variants sorbitol South Tablet Treatment variants variants of concern variants of concern. viral strain viruses [DOI] 10.3168/jds.2021-21247 PMC 바로가기 [Article Type] Article
Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies알파카 면역 레퍼토리의 다변량 마이닝은 강력한 교차 중화 SARS-CoV-2 나노바디를 식별합니다Article Published on 2022-03-252022-09-11 Journal: Science Advances [Category] MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus approach approach Beta Beta variant biochemical conserved Conventional coronavirus cross-neutralize cross-neutralizing deuterium epitope functional half-maximal inhibitory concentration hydrogen identify immune mass spectrometry monomeric multivariate nanobodies nanobody Neutralization assay neutralization assays neutralize Next-generation sequencing Other RBD Receptor binding domain receptor binding motif respiratory SARS-CoV-1 SARS-CoV-2 screening strategy side specificity the RBD the SARS-CoV-2 variant virus [DOI] 10.1126/sciadv.abm0220 PMC 바로가기 [Article Type] Article
Screening of Natural Products Inhibitors of SARS-CoV-2 EntryArticle Published on 2022-03-072022-10-30 Journal: Molecules [Category] COVID-19, MERS, SARS, [키워드] analyses Antiviral antiviral activity Biosafety Level 2 candidate Cell Compound Concentration COVID-19 pandemic D614G Diseases Entry inhibitor entry inhibitors evaluated fungi half-maximal inhibitory concentration HEK 293T HIV-1 indicate infect inhibiting inhibitor inhibitors inhibitory activity natural natural products plant product pseudotyped Pseudotyped virus SARS-CoV-2 SARS-CoV-2 entry SARS-COV-2 infection SARS-CoV-2 spike glycoprotein SARS-CoV-2 viral Screening Stachytarpheta target therapeutic virus virus [DOI] 10.3390/molecules27051743 PMC 바로가기 [Article Type] Article